<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117682">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570998</url>
  </required_header>
  <id_info>
    <org_study_id>117515</org_study_id>
    <nct_id>NCT01570998</nct_id>
  </id_info>
  <brief_title>Targeted Intraoperative Radiotherapy United States (TARGIT-US) Registry Trial</brief_title>
  <acronym>TARGIT-US</acronym>
  <official_title>Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Los Angeles Center for Women's Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to study the efficacy and toxicity of breast radiotherapy given
      intra-operatively as a single dose after breast conserving surgery, with or without whole
      breast radiation as indicated by pathologic risk factors, in women with early stage breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pragmatic registry trial has been designed and modeled after the original successful,
      international TARGIT-A protocol, to continue the use of intraoperative radiotherapy for a
      select population of women, and to follow outcomes with regards to local and regional
      control, toxicity and morbidity. Within this pragmatic single arm registry trial is a more
      selective approach that may be employed in some centers for some or all patients. Patients
      selected for breast conserving surgery who are considered to have a low risk of local
      recurrence are eligible for the registry trial once given their informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-breast local failure and patterns of in-breast failure</measure>
    <time_frame>1 month post-radiation therapy through year 5</time_frame>
    <description>Patients will be regularly monitored as per the individual center's policy provided this meets the minimum trial criteria for follow-up with physical examination at least every 6 months for 3 years and yearly at 4 and 5 years post-treatment. Confirmation of recurrence will follow clinical examination and cytology or biopsy. Site of relapse within the breast will be recorded in order to assess whether the recurrence is at the site of initial tumor or at a new site and whether it has occurred within the treated field.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity and morbidity</measure>
    <time_frame>1 month post-radiation therapy through 5 years</time_frame>
    <description>Local toxicity and morbidity will be recorded as adverse events related to the primary treatment of the breast cancer. These were recorded in the randomized trial and outcomes showed no significant difference in clinical complications for the IORT as compared to standard external beam radiation. However all expected toxicities of acute skin reaction, wound infection, wound breakdown, late skin reactions, and pain due to radiation will be graded according to RTOG criteria. All other toxicities will be recorded and graded according to standard NCI-CTCAE V. 4 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>1 month post-radiation therapy through 5 years</time_frame>
    <description>Relapse-free survival will be recorded as the time interval between trial entry and the date of confirmation of any recurrence. The actual date to be used is the clinic day on which the investigations that led to a confirmed diagnosis of the recurrence were requested. Relapse-free survival would include any recurrence of breast cancer (local,regional or distant) or death without prior report a relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 month post-radiation therapy through 5 years</time_frame>
    <description>Overall survival will be the time interval between enrollment and death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">755</enrollment>
  <condition>Malignant Neoplasm of Breast</condition>
  <condition>Breast Diseases</condition>
  <condition>Ductal Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Intraoperative radiation therapy (IORT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Intrabeam® Photon Radiosurgery System is a miniature electron beam-driven X-ray source which provides a point source of low energy X-rays (50 kV maximum) at the tip of a 3.2 mm diameter tube. The radiation source can be inserted into the area of interest immediately after excision of the tumor and switched on for 20-35 minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and early clinical applications of this device have been well studied and this is the device which was utilized in the international TARGIT trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intraoperative radiation therapy (IORT)</intervention_name>
    <description>The Intrabeam® Photon Radiosurgery System is a miniature electron beam-driven X-ray source which provides a point source of low energy X-rays (50 kV maximum) at the tip of a 3.2 mm diameter tube. The radiation source can be inserted into the area of interest immediately after excision of the tumor and switched on for 20-35 minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and early clinical applications of this device have been well studied and this is the device which was utilized in the international TARGIT trial.The Intrabeam is FDA approved for use in any part of the body. For breast irradiation, the radiation source is covered by a spherical applicator that is used to uniformly conform the lumpectomy cavity around the radiation source, enabling delivery of an accurately calculated dose to a prescribe depth.</description>
    <arm_group_label>Intraoperative radiation therapy (IORT)</arm_group_label>
    <other_name>intraoperative radiotherapy</other_name>
    <other_name>Zeiss Intrabeam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients aged 45 years or older with operable invasive breast cancer, T1 and T2
             (&lt; 3.5 cm), N0-1, M0, confirmed by cytological or histological examination, who are
             suitable for breast conserving surgery are eligible as long as they have had an
             ipsilateral diagnostic mammogram within 12 months of enrollment.

          -  Those with previously diagnosed and treated contralateral breast cancer may be
             entered.

          -  It is recommended that patients meet an ECOG performance status of 0-3, however,
             grade 4 patients can be treated at the discretion of the participating center.

          -  Individual centers may wish to restrict entry to a more exactly defined subset of
             patients in which case only patients with these characteristics may be entered by the
             particular center. For example, centers may decide at outset to recruit only women
             over the age of 50 or possibly only postmenopausal women. Before entering any patient
             into the trial, the local investigator should confirm that the patient would be
             available for regular follow-up for at least 5 years.

        Exclusion Criteria:

          -  Age &lt; 45 years

          -  Axillary lymph node positive breast cancer

          -  Invasive lobular cancer

          -  Tumor size &gt; 3.5 cm

          -  Extensive Intraductal Component (EIC= &gt; 25% of the lumpectomy specimen involved with
             ductal carcinoma in situ, DCIS) as assessed on surgical pathologic lumpectomy
             specimen

          -  Multicentric cancer in the same breast as diagnosed by clinical examination,
             mammography, ultrasound. MRI or pathologic assessment, not amenable to excision with
             negative margins with a single lumpectomy.

          -  Inability to assess pathologic margin status

          -  Bilateral breast cancer at the time of diagnosis.

          -  Ipsilateral breast had a previous cancer and/or prior in-field radiation.

          -  Patients known to have BRCA1/2 gene mutations (testing for gene mutations is not
             required).

          -  Patients undergoing primary systemic treatment (hormones or chemotherapy) as initial
             treatment with neoadjuvant intent of reducing tumor size.

          -  No more than 30 days can have elapsed between the last breast cancer surgery (not
             axillary) and entry into the trial for patients in the post-pathology stratification.

          -  Previous history of malignant disease does not preclude entry if the expectation of
             relapse-free survival at 10 years is 75% or greater

          -  Any factor included as exclusion criteria in the participating center's Treatment
             Policy Statement.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Alvarado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco Carol Franc Buck Breast Care, Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eleanor Harris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leo Jenkins Cancer Center, East Carolina University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Small, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis R Holmes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Center for Women's Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan Huang</last_name>
    <phone>(415) 353-7407</phone>
    <email>ryan.huang@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Celeste Long</last_name>
      <phone>510-204-3428</phone>
      <email>longca@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christine Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Angeles Women's Health Clinic of California Hospital Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MaryAnn Robertson</last_name>
      <phone>213-742-5526</phone>
      <email>MaryAnn.Robertson@Dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Dennis R Holmes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Lin</last_name>
      <phone>714-456-8329</phone>
      <email>erinhl@uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Carol Franc Buck Breast Care Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Huang</last_name>
      <phone>415-353-7407</phone>
      <email>ryan.huang@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Michael D Alvarado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Muir Medical Center</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Marquez, RN, BSN</last_name>
      <phone>925-674-2299</phone>
      <email>sheila.marquez@johnmuirhealth.com</email>
    </contact>
    <investigator>
      <last_name>Marjaneh Moini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Breast Center of Greenwich Hospital</name>
      <address>
        <city>Greenwich</city>
        <state>Connecticut</state>
        <zip>06830</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennie Melendez</last_name>
      <phone>203-863-3767</phone>
      <email>Jennie.Melendez@greenwichhospital.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sulakshana Seevaratnam</last_name>
      <phone>202-444-1721</phone>
      <email>Sulakshana.Seevaratnam@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Shawna Wiley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Timothee</last_name>
      <phone>202-877-3061</phone>
      <email>Patricia.timothee@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Marc Boisvert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eileen Georgi</last_name>
      <phone>954-267-7748</phone>
      <email>eileen.georgi@holy-cross.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Casey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Sather</last_name>
      <phone>912-350-5664</phone>
      <email>SatheKa1@memorialhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Chiappetta, RN</last_name>
      <phone>708-216-2568</phone>
      <email>bchiapetta@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>William Small, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Prescott</last_name>
      <phone>312-926-3116</phone>
      <email>Adam.Prescott@nm.org</email>
    </contact>
    <investigator>
      <last_name>Eric Donnelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Health Network</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa McVicker</last_name>
      <phone>317-621-7104</phone>
      <email>lmcvicker@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>Chase Lottich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Gerbasio</last_name>
      <phone>410-951-7908</phone>
      <email>agerbasi@mdmercy.com</email>
    </contact>
    <investigator>
      <last_name>Neil Friedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawn Regis</last_name>
      <phone>781-744-7890</phone>
      <email>Shawn.M.Regis@Lahey.org</email>
    </contact>
    <investigator>
      <last_name>Rebecca Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John's Riverside Health Hospital - Ashikari Breast Center, Dobbs Ferry</name>
      <address>
        <city>Dobbs Ferry</city>
        <state>New York</state>
        <zip>10522</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julissa Cruz</last_name>
      <phone>914-693-5025</phone>
      <email>jcruz@riversidehealth.org</email>
    </contact>
    <investigator>
      <last_name>Pond Kelemen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delcia Rivas</last_name>
      <phone>212-305-9490</phone>
      <email>dr2570@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Eileen Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoely Tavarez</last_name>
      <email>yot2002@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Mary Kay Hayes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vassar Brothers Medical Center</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Elkarra</last_name>
      <phone>845-483-6923</phone>
      <email>nelkarra@health-quest.org</email>
    </contact>
    <investigator>
      <last_name>Angela Keleher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Green</last_name>
      <phone>216-444-3159</phone>
      <email>greenh@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Stephanie Valente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital and Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carolyn Seith</last_name>
      <phone>484-503-4153</phone>
      <email>carolyn.seith@sluhn.org</email>
    </contact>
    <investigator>
      <last_name>Lee Riley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INOVA Dwight and Martha Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Turner</last_name>
      <phone>703-970-6488</phone>
      <email>Lindsey.Turner@inova.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meredith Strand</last_name>
      <email>MBSTRAND@sentara.com</email>
    </contact>
    <investigator>
      <last_name>Richard Hoefer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora BayCare Medical Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Reed</last_name>
      <phone>920-288-3592</phone>
      <email>Kathy.Reed@aurora.org</email>
    </contact>
    <investigator>
      <last_name>William Owens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010 Jul 10;376(9735):91-102. doi: 10.1016/S0140-6736(10)60837-9. Erratum in: Lancet. 2010 Jul 10;376(9735):90.</citation>
    <PMID>20570343</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 20, 2016</lastchanged_date>
  <firstreceived_date>March 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Disease-Free Survival</keyword>
  <keyword>Female</keyword>
  <keyword>Humans</keyword>
  <keyword>Intraoperative Care</keyword>
  <keyword>Mastectomy Segmental</keyword>
  <keyword>Middle Aged</keyword>
  <keyword>Neoplasm Recurrence Local</keyword>
  <keyword>Radiotherapy Dosage</keyword>
  <keyword>Radiotherapy Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
    <mesh_term>Breast Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
